clinical trial · NCT04634539
Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
Jun Gong, MD·phase1·completed·n = 18
Advanced Pancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaGemcitabineNab-paclitaxelL-glutamine
brief summary
This study will enroll a total of 16 patients with advanced pancreatic cancer at Cedars-Sinai Medical Center. All subjects will receive combination therapy of gemcitabine, nab-paclitaxel, and L-glutamine. The study investigates what the appropriate dosage of L-glutamine is so that there is the lowest risk of side effects, and whether the supplement will make standard chemotherapy of gemcitabine and nab-paclitaxel more effective in treating advanced pancreatic cancer.
started
May 13, 2021
primary completion
Jul 6, 2023
completion
Jun 17, 2025
last updated
Aug 6, 2025
official title
IIT2020-02-Gong-GlutaPanc: Phase I Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (GlutaPanc)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol